Bridgeway Capital Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $332,820 - $655,965	-193,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $415,500 - $546,000	150,000 Added 344.83%	193,500 $602,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $140,505 - $200,099	43,500 New	43,500 $147,000
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $562,823 - $886,962	-98,224 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $1.33 Million - $2.89 Million	-399,300 Reduced 80.26%	98,224 $711,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $482,958 - $1.46 Million	342,524 Added 220.98%	497,524 $1.74 Million
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $153,250 - $247,652	-122,600 Reduced 44.16%	155,000 $229,000
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $369,208 - $1.65 Million	277,600 New	277,600 $544,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.